Eli Lilly (LLY)

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most critical juncture in its nine-year history. Once viewed as a disruptive "millennial-focused" telehealth startup specializing in hair loss and sexual health, the company [...]

In a matter of months, last year's winners have shifted to losers, creating compelling buying opportunities for long-term investors.

Eli Lilly may be the GLP-1 leader, but its valuation is stretched.

This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.

These companies have a lot more to offer than their prospects in the weight loss market.

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Things can't get that much worse for the drugmaker.

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international equity markets are not just keeping pace with their American counterparts but are decisively outperforming them. While

Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Bristol-Myers Squibb (NYSE:BMY) and its peers.

As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the boardroom have returned with a vengeance. Leading investment banks, including Morgan Stanley (NYSE: MS), are now projecting a staggering

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at a crossroads, battling

As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the index will reach 7,800—a bold 14% gain from current levels. This bullish stance